Skip to content

    Recently Viewed


      Four scientists in white lab coats working at separate stations in a laboratory

      Working with the Senate HELP Committee

      Johnson & Johnson has accepted the Senate HELP Committee’s invitation for our Chairman and CEO to participate in a hearing and look forward to building an understanding of our longstanding efforts to improve affordability and access to medicines.

      Statement of Joaquin Duato Chairman and Chief Executive Officer Johnson & Johnson

      Fast facts about J&J Drug Prices and R&D investments PDF

      2022 U.S. Transparency Report

      Our net prices declined for the sixth year in a row in 2022. Unfortunately, the reality for millions of patients is growing affordability and health equity gaps caused by underinsurance and inadequate insurance benefit design driven by middlemen, including pharmacy benefit managers.

      Executive Summary
      drug price hearing johnson & johnson 2022 transparency report

      Our letter to the Committee

      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.